| No images? Click here  Thursday, 21 November 2024 MEDIA ADVISORY WHO's Science in 5: Is COPD making you breathless and tired? If you are experiencing breathlessness and fatigue and are exposed to polluted air, you could have Chronic Obstructive Pulmonary Disease (COPD). Dr Sarah Rylance explains the symptoms, treatment and prevention of COPD - find out if you are more susceptible to COPD in Science in 5. Closed captioning is available for Science in 5 in several languages on YouTube.
Thank you for amplifying through your networks. Science in 5 is WHO's conversation in science. In this video and podcast series WHO experts explain the science related to COVID-19 and other issues. The series is available every week on WHO's YouTube, Instagram, Facebook, Twitter, and LinkedIn channels and on all major podcasts platforms. For media partnerships for embedding this series, please contact us at: communications@who.int More information: https://www.who.int/podcasts/series/science-in-5.  Media contact:  You are receiving this NO-REPLY email because you are included on a WHO mail list.  |
Thursday, November 21, 2024
WHO's Science in 5: Is COPD making you breathless and tired?
Tuesday, November 19, 2024
News Release: WHO Investment Round: culminating moment at G20 Summit as leaders pledge
| No images? Click here  Tuesday, 19 November 2024 News releaseWHO Investment Round: culminating moment at G20 Summit as leaders pledge19 November 2024: Rio de Janeiro The first-ever Investment Round of the World Health Organization (WHO) reached a culminating moment during the G20 Leaders' Summit today in Rio de Janeiro, chaired by the President of Brazil, H.E. Luiz Inácio Lula da Silva. Heads of state and government at the G20 voiced strong support for a sustainably funded WHO, additional financial pledges were announced, and incoming G20 Chair South Africa pledged to maintain a focus in 2025 on sustainably financing the Organization. The support was reflected in the G20 Rio de Janeiro Leaders’ Declaration which said: “We reiterate the central coordinating role of the World Health Organization (WHO) in the global health architecture, supported by adequate, predictable, transparent, flexible and sustainable financing. We support the conducting of the WHO Investment Round as an additional measure for financing the WHO activities.” The Investment Round is raising funds for WHO’s strategy for global health, the Fourteenth General Programme of Work, which can save an additional 40 million lives over the next four years. The Investment Round has succeeded in shifting WHO’s funding model so that it is more predictable, flexible and resilient. With the pledges received from Australia, Indonesia and Spain at the Leaders’ Summit, WHO has now received pledges of US$ 1.7 billion. Including other signed funding agreements and expected funding from partnerships, WHO has funding of US$ 3.8 billion for the next four years. This means that WHO has raised 53% of the US$ 7.1 billion funding needed, successfully increasing predictability as compared to 2020, when WHO had only 17% of funding secured for its previous strategy. WHO, Member States and partners will continue efforts to cover the remaining gap so the Organization can deliver on the strategy for 2025–2028. The Investment Round has also successfully broadened WHO’s donor base, improving its funding resilience. Since its launch in May, there have been 70 new pledges from Member States, and philanthropic and private sector donors, 39 of which are contributing voluntary funds for the first time. This is making WHO’s funding more diversified and thus marks a milestone in the Organization’s evolution. Seven of these new donors are low-income countries and 21 are middle-income countries, representing a shift in WHO’s funding base. This shift also demonstrates broad-based recognition of the need to invest in health and in WHO. Forty-six donors have so far pledged more flexible funding, compared to 35 in the last four years, increasing the ability of WHO to use the funds where they are most needed. Overall, the Investment Round means that WHO can work more efficiently, better plan the implementation of its Strategy and respond even better to crises. It is expected that a number of other governments and donors will pledge to the Investment Round in the coming months. Quotes: President of Brazil, H.E. Luiz Inácio Lula da Silva, said: “The World Health Organization represents humanity’s greatest ideals. Investment over the next four years will be repaid many times over in well-being gained. It will set the foundation for future generations.” The Chancellor of the Federal Republic of Germany, Olaf Scholz, said: “The work of the WHO benefits all of us. It needs reliable financing from a broad base. Every contribution counts." President of France, Emmanuel Macron, said: “The World Health Organization deserves our support, as our unique common, universal, compass to global health. It is the only organization technically and politically able to coordinate our global action, and edict universal norms and advice in the field of health. As part of this Investment Round, WHO is bringing to life a new Academy, open to all health practitioners around the world, to tackle one of the key investment priorities identified during the COVID crisis, which is human capacity in the health sector. In a nutshell, investing in WHO is investing in the strengthening of our response capacity to health crises and in particular to pandemics.” President of South Africa H.E. Cyril Ramaphosa, who will Chair the G20 Presidency in 2025, said: “We are proud to carry the baton on from Brazil and continue to spotlight the importance of WHO and the need for sustainable financing towards the goal of health for all.” “The WHO Investment Round is about mobilizing the predictable, flexible funding WHO needs to save lives, prevent disease and make the world a healthier and safer place,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “I thank President Lula for his strong support for WHO and for hosting the culmination of the Investment Round during the G20 Leaders’ Summit, and I thank all donors for their contributions. I am grateful to President Ramaphosa for carrying the baton for sustainable financing for WHO into South Africa’s G20 Presidency next year.” Related WHO's Investment Round - Voices of support G20 Rio de Janeiro Leaders’ Declaration WHO Director-General's remarks at the G20 Leaders’ Summit – 18 November 2024 News G20 health ministers rally support for WHO’s Investment Round 1 November 2024  WHO media contact:  You are receiving this NO-REPLY email because you are included on a WHO mail list.  |
News Release: WHO adds LC16m8 mpox vaccine to Emergency Use Listing
| No images? Click here  Tuesday, 19 November 2024 News releaseWHO adds LC16m8 mpox vaccine to Emergency Use ListingThe World Health Organization (WHO) has granted Emergency Use Listing (EUL) for the LC16m8 mpox vaccine, making it the second mpox vaccine to be supported by WHO following the Director-General’s declaration of an mpox public health emergency of international concern (PHEIC) on 14 August 2024. This decision is expected to facilitate increased and timely access to vaccines in communities where mpox outbreaks are surging. In 2024, cases have been reported across 80 countries, including 19 countries in Africa, based on data as of 31 October 2024. The Democratic Republic of the Congo, the hardest-hit country, recorded a large majority of suspected cases – over 39 000 – as well as more than 1000 deaths. Today’s move is particularly relevant as the Government of Japan has announced that it will donate 3.05 million doses of the LC16m8 vaccine, along with specialized inoculation needles, to the Democratic Republic of the Congo. This is the largest donation package announced to date in response to the current mpox emergency. LC16m8 is a vaccine developed and manufactured by KM Biologics in Japan. The Technical Advisory Group (TAG) for EUL of vaccines convened to discuss the outcome of the LC16m8 vaccine review, including the product and programmatic suitability assessments. The TAG recommended the vaccine for use in individuals over one year of age as a single dose vaccine, via a multiple puncture technique using a bifurcated needle. “WHO emergency use listing of the LC16m8 vaccine against mpox marks a significant step in our response to the current emergency, providing a new option to protect all populations, including children,” said Dr Yukiko Nakatani, WHO Assistant Director-General for Access to Medicines and Health Products. “Vaccines are one of the important tools to help contain the outbreak as part of a comprehensive response strategy that also includes improved testing and diagnosis, treatment and care, infection prevention control, and engagement and education within affected communities.” WHO’s assessment for EUL is based on information submitted by the manufacturer and review by the Pharmaceuticals and Medical Devices Agency (PMDA), the Japanese regulatory agency of record for this vaccine. The LC16m8 vaccine has been used in Japan during previous mpox outbreaks and was shown to be safe and effective, including in people with well-controlled HIV. The WHO Strategic Advisory Group of Experts (SAGE) on Immunization reviewed available evidence and recommended the use of LC16m8 vaccine in outbreak settings in children and others with a documented high-risk of exposure to mpox. However, minimally replicating vaccines, such as LC16m8, should not be used during pregnancy and in people who are immunocompromised. Immunocompromised persons include those with active cancer, transplant recipients, immunodeficiency, and active treatment with immunosuppressive agents. They also include people living with HIV with a current CD4 cell count of <200 cells µl. The Global Advisory Committee on Vaccine Safety reviewed the updated safety data on LC16m8 on 20 September 2024 and recommended that healthcare workers are provided with training on the use of bifurcated needles to prevent injuries and adverse effects. In light of the changing epidemiology and emergence of new virus strains, it remains important to collect as much data as possible on vaccine safety and effectiveness in different contexts. WHO continues to work closely with manufacturers, global partners and countries to ensure the availability and administration of safe and effective life-saving products. On 13 September 2024, WHO prequalified the Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine and expanded its indication to include use in individuals aged 12 years and older on 8 October 2024. Note to editors: WHO Prequalification (PQ) and Emergency Use Listing (EUL) are mechanisms used to evaluate quality, safety and efficacy of medical products, such as vaccines, diagnostics and medicines, and product suitability for use in the contexts of low- and middle-income countries. Products receiving PQ or EUL support decision-making for international, regional and country procurement by UN and partner procurement agencies and Member States. PQ is based on the review of full set of quality, safety and efficacy data on medical products, including risk management plan and programmatic suitability. EUL is a risk benefit assessment to address urgent demands during public health emergencies based on available limited data where the benefits outweigh the risks.
 WHO media contact:  You are receiving this NO-REPLY email because you are included on a WHO mail list.  |
Webinar on Post COVID-19 Condition: Science, Research and Policy, 16.00 CET on 20 November 2024
| No images? Click here  Tuesday, 19 November 2024 MEDIA ADVISORY Webinar on post COVID-19 condition: Science, research and policy What: This webinar will provide an update on global scenario of research on post COVID-19 condition (also referred to as Long Covid), what we have learnt so far, and initiatives to support patient care with long COVID. When: 16.00 to 17.00 CET on 20 November Real-time interpretation into Spanish, French, Portuguese, and Arabic is provided. Additional information and registration: https://www.who.int/news-room/events/detail/2024/11/20/default-calendar/post-covid-19-condition-science-research-and-policy  WHO media:  You are receiving this NO-REPLY email because you are included on a WHO mail list.  |
MEDIA ADVISORY: Announcement on WHO Investment Round, 21.00 CET/17.00 BRT (Rio), 19 November
| No images? Click here  Tuesday 19 November 2024 MEDIA ADVISORY Announcement on WHO Investment Round WHEN: Tuesday, 19 November at 21.00 CET/17.00 BRT (Rio) WHAT: President of Brazil H.E. Luiz Inácio Lula da Silva, G20 Leaders' Summit Chair, will announce the outcome of the WHO Investment Round today. WHO Director-General, Dr Tedros Adhanom Ghebreyesus will also join. WHERE: WHO’s social media channels: X and YouTube and on WHO Director-General’s accounts: X, LinkedIn, and Facebook Speakers will include:
Also see:
 WHO media:  You are receiving this NO-REPLY email because you are included on a WHO mail list.  |
